Ardelyx, Inc.

NASDAQ:ARDX

Biotechnology

Healthcare
$3.12 -1.03%

-$0.06 today

Market cap
$784.28M
Beta
0.58
P/E (TTM)
-24.5
EPS (TTM)
-$0.24
52W Low $3.49High $8.40

Volume 4.75M

Average 3.58M

ARDX Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Ardelyx, Inc.NASDAQ: ARDX

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows in line with its trailing trend

Q1 FY2026 weighted avg shares of 245.86M shares rose 3.0% year over year, in line with the +2.6% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.9% from the prior quarter. Over 3 fiscal years it compounded at +15.0% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +3.0% holds above the trailing-twelve-month pace of +2.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
245.86M+0.9% QoQ
Last fiscal yearDec 2025
241.03M+2.5% YoY
LTMMar 2026
242.83M+2.6% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.0%——
1 year+2.5%——
3-year CAGR+15.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
241.03M USD
Year-over-year change
+2.5%
4-year CAGR
+23.3%

Weighted Avg Shares vs competitors

How ARDX compares with its peers on the latest reported figures

  • ARDX's LTM Mar 2026 weighted avg shares of 242.83M shares is the 2nd highest of the 5 companies compared; the peer median is 107.93M shares.
  • Its year-over-year change of +2.6% is the lowest of 5, against a peer median of +14.0%.
  • Over three fiscal years its annual growth of +15.0% compares with a peer median of +8.9%.
ARDX Competitors Peer median
Weighted Avg Shares for ARDX and competitors
Company Period LTM YoY 3-year CAGR
AKBAAkebia Therapeutics, Inc.LTM Mar 2026264.94M +21.2%+12.1%
ARDXArdelyx, Inc.LTM Mar 2026242.83M +2.6%+15.0%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026167.52M +11.9%+5.8%
DMACDiaMedica Therapeutics Inc.LTM Mar 202648.34M +16.1%+21.1%
MAZEMaze Therapeutics, Inc.LTM Mar 202646.63M +6.5%-0.6%
Peer median (excluding ARDX) 107.93M+14.0%+8.9%

Competitors are the stored peer set for ARDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.1M52.16M124.46M333.62M407.32M
Cost of Revenue1M4.12M17.8M50.56M42.6M
Gross Profit9.1M48.04M106.66M283.06M364.72M
Gross Margin90.1%92.1%85.7%84.8%89.5%
Research & Development91.14M35.2M35.54M52.32M68.47M
Selling, General & Admin72.3M76.6M134.4M258.69M337.23M
Operating Expenses163.44M111.8M169.94M311.01M405.7M
Depreciation & Amortization2.81M1.14M1.29M2.06M3.06M
EBITDA(150.85M)(60.98M)(55.35M)(16.71M)(29.17M)
EBITDA Margin-1494.0%-116.9%-44.5%-5.0%-7.2%
Operating Income(154.35M)(63.76M)(63.28M)(27.95M)(40.98M)
Operating Margin-1528.6%-122.2%-50.8%-8.4%-10.1%
Interest Income00000
Interest Expense4.5M5.07M8.87M20.09M28.4M
Other Income / Expenses(3.82M)(3.44M)(2.24M)(10.92M)(19.65M)
Income Before Tax(158.16M)(67.2M)(65.52M)(38.87M)(60.63M)
Pre-Tax Margin-1566.4%-128.8%-52.6%-11.7%-14.9%
Income Tax Expense4K8K547K266K969K
Net Income(158.17M)(67.21M)(66.07M)(39.14M)(61.6M)
Net Margin-1566.5%-128.9%-53.1%-11.7%-15.1%
EPS (Basic)(1.52)(0.42)(0.30)(0.17)(0.26)
EPS (Diluted)(1.52)(0.42)(0.30)(0.17)(0.26)
Weighted Avg Shares104.21M158.69M219.33M235.23M241.03M
Weighted Avg Shares (Diluted)104.21M158.69M219.33M235.23M241.03M

Ardelyx, Inc.

NASDAQ:ARDX

Intrinsic Alpha fair value

Locked

Current Price

$3.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.